Citations

Clear

1134 citation(s) found for "Li, Yan".

Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas
Wickland, Daniel P. , Sherman, Mark E. , Mansfield, Aaron S. , Asmann, Yan W. , Radisky, Derek C. , Mansfield, Aaron S , Asmann, Yan W

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 10, 2022 | Volume: 114 | Issue: 8 | Pages: 1192-1199

10.1093/jnci/djac054 | PMID 35299252 Get It

Abstract Background In the United States, cancer disproportionately impacts Black and African American individuals. Identifying genetic factors underlying cancer disparities has been an important research focus and requires data that are equitable in both quantity and quality across racial groups. It is widely recognized that DNA databases quantitatively underrepresent minorities. However, the differences in data quality between racial groups have not been well studied. Methods We compared the qualities of germline and tumor exomes between ancestrally African and European patients in The Cancer Genome Atlas of 7 cancers with at least 50 self-reported Black patients in the context of sequencing depth, tumor purity, and qualities of germline variants and somatic mutations. Results Germline and tumor exomes from ancestrally African patients were sequenced at statistically significantly lower depth in 6 out of the 7 cancers. For 3 cancers, most ancestrally European exomes were sequenced in early sample batches at higher depth, whereas ancestrally African exomes were concentrated in later batches and sequenced at much lower depth. For the other 3 cancers, the reasons of lower sequencing coverage of ancestrally African exomes remain unknown. Furthermore, even when the sequencing depths were comparable, African exomes had disproportionally higher percentages of positions with insufficient coverage, likely because of the known European bias in the human reference genome that impacted exome capture kit design. Conclusions Overall and positional lower sequencing depths of ancestrally African exomes in The Cancer Genome Atlas led to underdetection and lower quality of variants, highlighting the need to consider epidemiological factors for future genomics studies.
Birt-Hogg-Dubé Syndrome Encountered At Rare Lung Disease Clinic In Anhui Province, China
Zhang, Guofeng , Liu, Jinli , Wang, Yushuo , Wang, Yue , Jiang, Xianliang, Peng, Yan, Xiao, Jun , Wei, Wei , Shen, Bing , Yi, Long, Ryu, Jay H. , Ryu, Jay H , Hu, Xiaowen

Mayo Clinic

No container title available | March 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1319752/v1 Get It

Abstract Background: Diagnosis of rare diseases remains a challenge in China. We describe our experience with Birt-Hogg-Dubé syndrome (BHDS) encountered at a Rare Lung Disease Clinic recently established in China.Methods: After the first patient with BHDS was recognized in 2017, a Rare Lung Disease Clinic with a multidisciplinary team of specialists was established. We retrospectively analyzed the data of consecutive patients with BHDS encountered from inception to December 2021.Results: There were 1, 1, 15, 12 and 21 cases with BHDS diagnosed from year 2017 to 2021, respectively. All 50 patients (34 women) were of Han race with a mean age of 47.3 years. The common manifestations were pulmonary cysts (98%), pneumothorax (54%) and skin lesions (68%). Renal cancer was detected in two patients and renal angiomyolipoma in four other patients. The main presentations leading to diagnosis were pneumothorax (42%), family screening (36%) and lung cysts identified on radiologic imaging (20%). The average delay in diagnosis was 8.3 years, and 4.7 years in patients with only pulmonary cysts. The most frequent pathogenic variant was c.1285del/dup on exon 11 (23%) among 44 patients confirmed by genetic testing. Renal cancer has not been found on follow-up surveillance thus far.Conclusions: There has been increasing number of patients with BHDS recognized in China, facilitated by establishment of a Rare Lung Disease Clinic. Pulmonary cysts and pneumothorax were commonly encountered features, but skin lesions appeared to be more prevalent in Chinese subjects than previously reported in other Asian countries.
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma
Mladek, Ann C. , Yan, Huihuang , Tian, Shulan , Decker, Paul A. , Hu, Zeng, Connors, Margaret A. , Carlson, Brett L. , Wilson, Jonathan E. , Bommi‐Reddy, Archana, Conery, Andy, Eckel‐Passow, Jeanette E. , Kitange, Gaspar J. , Burgenske, Danielle M. , Bakken, Katrina, Sarkaria, Jann N , Mladek, Ann C , Decker, Paul A. , Bakken, Katrina K. , He, Lihong , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | February 28, 2022 | Volume: 24 | Issue: 8 | Pages: 1261-1272

10.1093/neuonc/noac051 | PMID 35231103 Get It

Abstract Background RBBP4 activates transcription by histone acetylation, but the partner histone acetyltransferases are unknown. Thus, we investigated the hypothesis that RBBP4 interacts with p300 in a complex in glioblastoma (GBM). Methods shRNA silencing of RBBP4 or p300 and RNAseq was used to identify genes co-regulated by RBBP4 and p300 in GBM43 patient-derived xenograft (PDX). RBBP4/p300 complex was demonstrated using proximity ligation assay (PLA) and ChIPseq delineated histone H3 acetylation and RBBP4/p300 complex binding in promoters/enhancers. Temozolomide (TMZ)-induced DNA double strand breaks (DSBs) were evaluated by γ-H2AX and proliferation by CyQuant and live cell monitoring assays. In vivo efficacy was based on survival of mice with orthotopic tumors. Results shRBBP4 and shp300 downregulated 4768 genes among which 1485 (31%) were commonly downregulated by both shRNAs, while upregulated genes were 2484, including 863 (35%) common genes. The pro-survival genes were the top-ranked among the downregulated genes, including C-MYC. RBBP4/p300 complex was demonstrated in the nucleus, and shRBBP4 or shp300 significantly sensitized GBM cells to TMZ compared to the control shNT in vitro (P < .05). Moreover, TMZ significantly prolonged the survival of mice bearing GBM22-shRBBP4 orthotopic tumors compared with control shNT tumors (median shNT survival 52 days vs. median shRBBP4 319 days; P = .001). CREB-binding protein (CBP)/p300 inhibitor CPI-1612 suppressed H3K27Ac and RBBP4/p300 complex target proteins, including C-MYC, and synergistically sensitized TMZ in vitro. Pharmacodynamic evaluation confirmed brain penetration by CPI-1612 supporting further investigation to evaluate efficacy to sensitize TMZ. Conclusions RBBP4/p300 complex is present in GBM cells and is a potential therapeutic target.
Ptf1a Promoter-Driven Cre Expression During Spermatogenesis Causes Germline Recombination
Wang, Jiale, Wang, Oliver, Bi, Yan, Wang, Ying, Crawford, Howard, Ji, Baoan, Wang, Jiale , Wang, Jiale , Wang, Jiale, Wang, Oliver, Bi, Yan, Wang, Ying, Crawford, Howard, Ji, Baoan

Mayo Clinic

Pancreas | February 23, 2022 | Volume: 51 | Issue: 1 | Pages: 90-93

10.1097/mpa.0000000000001961 | PMID 35195600 Get It

Objectives Two independently developed Ptf1a-Cre mouse lines, Ptf1atm1(cre)Hnak and Ptf1atm1(Cre)Cvw, are widely used in pancreatic research. Recently, Ptf1atm1(cre)Hnak line was reported to transmit unwanted paternal recombination. We aimed to investigate whether this exists in the Ptf1atm1(Cre)Cvw line. Methods Ptf1atm1(Cre)Cvw mice were crossed with R26-LSL-LacZ reporter mice. DNA recombination and gene expression were examined by recombination-specific polymerase chain reaction, reverse transcription–polymerase chain reaction, and X-Gal staining. Results R26 locus recombination was detected in the pancreas as well as the testes and sperm of the double transgenic mice. Positive ptf1a mRNA expression from testes revealed that there was endogenous Ptf1a promoter activity in this extrapancreatic tissue. Of the 15 progenies that inherited LacZ from the male double transgenic mice, 4 (26.7%) were positive for complete whole-body recombination. The presence of recombination in R26 only mice suggested that the recombination occurred before meiosis. Conclusions Paternal germline recombination exists in the Ptf1atm1(Cre)Cvw mouse line. Ptf1a promoter-driven Cre expression during spermatogenesis before meiosis is the cause of germline recombination. Therefore, when male Ptf1a-Cre mice are used in compound mice breeding, it is necessary to genotype not only floxed alleles but also recombined alleles to examine unwanted recombinations.
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
Kuruvilla, John , Bijou, Fontanet , Santoro, Armando , Boccomini, Carola , Kenkre, Vaishalee P. , Isufi, Iris, Andorsky, David , Klein, Leonard M., Greenwald, Daniel, Sangha, Randeep, Shen, Frank, Hagner, Patrick R. , Dobmeyer, Juergen, Gong, Nian , Uttamsingh, Shailaja, Pourdehnad, Michael , Kuruvilla, John , Ribrag, Vincent , Santoro, Armando , Nastoupil, Loretta J. , Chavez, Julio C , Witzig, Thomas E. , Flinn, Ian W. , Corradini, Paolo , Li, Yan , Gong, Nian

Mayo Clinic

eJHaem | February 15, 2022 | Volume: 3 | Issue: 2 | Pages: 394-405

10.1002/jha2.394 | PMID 35846031 Get It

AbstractThe multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received avadomide 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m2 on day 8 of cycle 1, day 1 of cycles 2 through 6, and day 1 of every third subsequent cycle for 2 years. Primary endpoints were safety and tolerability; preliminary efficacy was a secondary endpoint. A total of 68 patients were enrolled (DLBCL [n = 27], FL [n = 41; 31 lenalidomide‐naïve, 10 lenalidomide‐treated]). Median age was 62 years (range, 33–84 years), and patients had received a median of 3 (range, 1–8) prior regimens. Among patients with DLBCL, 66.7% had primary refractory disease (partial response or less to initial therapy). Among patients with FL, 65.9% were rituximab‐refractory at study entry and 10.0% were lenalidomide‐refractory. The most common any‐grade avadomide‐related adverse events (AEs) were neutropenia (63.2%), infections/infestations (23.5%), fatigue (22.1%), and diarrhea (19.1%). The most common grade 3/4 avadomide‐related AEs were neutropenia (55.9%) infections/infestations (8.8%), and febrile neutropenia (7.4%). In patients with DLBCL, overall response rate (ORR) was 40.7% and median duration of response (mDOR) was 8.0 months. In patients with FL, ORR was 80.5% and mDOR was 27.6 months; response rates were similar in lenalidomide‐naïve and ‐treated patients. Avadomide plus rituximab was well tolerated, and preliminary antitumor activity was observed in patients with R/R DLBCL and FL, including subgroups with typically poor outcomes. These results support further investigation of novel CELMoD agents in combination with rituximab in R/R DLBCL and FL.
Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade
Maus, Rachel L.G., Leontovich, Alexey A. , Moore, Raymond M. , Becher, Laura , Nevala, Wendy K. , Flotte, Thomas J. , Guo, Ruifeng , Dicke, Betty A., Yan, Yiyi , Leontovich, Alexey L, Schimke, Jill, Guo, Ruifeng , Schimke, Jill M. , Markovic, Svetomir N.

Mayo Clinic

Cancer Research Communications | February 10, 2022 | Volume: 2 | Issue: 2 | Pages: 78-89

10.1158/2767-9764.crc-21-0146 | PMID 35992329 Get It

Direct interactions between tumor and immune cells mediate the antitumor effect of all modern cancer immunotherapeutic agents. Simultaneously, tumor cells have evolved mechanisms of evasion, including the downregulation of HLA-I, potentially disrupting the mechanism of action employed by many immune checkpoint inhibitors. And yet, the in situ interplay between these cells within the tumor immune microenvironment (TIME) remains elusive. Recent advances in histologic multiplex bioimaging platforms have enabled in-depth molecular characterization of single cells within spatially preserved and clinically archived tumor tissues. Herein, we applied multiplex immunofluorescence to excisional lymph node biopsies from 14 patients with metastatic melanoma who experienced clear objective responses to immunotherapy (7 complete response; 7 progressive disease) to determine distinguishing features of the TIME in the pretreatment setting. Distinct regions of the TIME were evaluated using 35 proteins probing tumor, immune, and vasculature components across 323 fields of view. Single-cell compositional analysis confirmed established prognostic immune cell types including increased prevalence of cytotoxic T cells within the tumor core fields of view of responders. Integrating single-cell quantification with the spatial arrangement of cellular neighborhoods surrounding tumor cells revealed novel, spatial immune signatures capable of stratifying TIME based on clinical response. Our analysis revealed dynamic cellular composition of the tumor-centric cellular neighborhood (TCCN) based on anatomic subregion, functional expression of HLA-I by the index tumor cell and ultimately clinical response to immunotherapy. Overall, this study provides an analytic framework to resolve the cellular complexity of the TIME, increasingly relevant to the outcomes of modern cancer immunotherapy. Significance: Findings from this work propose a novel approach to resolving clinical heterogeneity of the TIME by objectively quantifying the cellular interactions occurring in metastatic melanoma lymph node tissue utilizing multiplex immunofluorescence. This study provides an analytic and biologically derived unit of measure, the TCCN which is customizable for studying critical paracrine interactions within spatially preserved tissue of various cancers and across the spectrum of multiplex imaging modalities.
Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies
Doubeni, Chyke A. , Pennello, Gene , Carlson, Robert W. , Lau, Yan Kwan, Pennello, Gene A , Carlson, Robert W , Lau, Yan Kwan , Lin, Jennifer S , Doubeni, Chyke A.

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 883-891

10.1002/cncr.33954 | PMID 35133658 Get It

Multicancer screening is a promising approach to improving the detection of preclinical disease, but current technologies have limited ability to identify precursor or early stage lesions, and approaches for developing the evidentiary chain are unclear. Frameworks to enable development and evaluation from discovery through evidence of clinical effectiveness are discussed.
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause – the Cardiogenic Shock Score
Beer, Benedikt N. , Weimann, Jessica , Dabboura, Salim , Yan, Isabell , Sundermeyer, Jonas , Blankenberg, Stefan , Schrage, Benedikt , Westermann, Dirk , Schrage, Benedikt , Westermann, Dirk , Blankenberg, Stefan , Jentzer, Jacob C. , Kirchhof, Paulus

Mayo Clinic

European Journal of Heart Failure | February 4, 2022 | Volume: 24 | Issue: 4 | Pages: 657-667

10.1002/ejhf.2449 | PMID 35119176 Get It

Aims Early risk stratification is essential to guide treatment in cardiogenic shock (CS). Existing CS risk scores were derived in selected cohorts, without accounting for the heterogeneity of CS. The aim of this study was to develop a universal risk score (the Cardiogenic Shock Score, CSS) for all CS patients, irrespective of the underlying cause. Methods and results Within a registry of 1308 CS unselected patients admitted to a tertiary care hospital between 2009 and 2019, a Cox regression model was fitted to derive the CSS, with 30‐day mortality as main outcome. The CSS's predictive ability was compared to the IABP‐SHOCK II score, the CardShock score and SCAI classification by C‐indices and validated in an external cohort of 934 CS patients. Based on the Cox regression, nine predictors were included in the CSS: age, sex, acute myocardial infarction (AMI‐CS), systolic blood pressure, heart rate, pH, lactate, glucose and cardiac arrest. The CSS had the highest C‐index in the overall cohort (0.740 vs. 0.677/0.683 for IABP‐SHOCK II score/CardShock score), in patients with AMI‐CS (0.738 vs. 0.675/0.689 for IABP‐SHOCK II score/CardShock score) and in patients with non‐AMI‐CS (0.734 vs. 0.677/0.669 for IABP‐SHOCK II score/CardShock score). In the external validation cohort, the CSS had a C‐index of 0.73, which was higher than all other tested scores. Conclusion The CSS provides improved information on the risk of death in unselected patients with CS compared to existing scores, irrespective of its cause. Because it is based on point‐of‐care variables which can be obtained even in critical situations, the CSS has the potential to guide treatment decisions in CS.
Immediate Breast Reconstruction Using the Goldilocks Procedure: A Balance between More Surgery and Patient Satisfaction
Manrique, Oscar J. , Yan, María , Bustos, Samyd S. , Harless, Christin A., Tran, Nho V. , Martinez‐Jorge, Jorys, Forte, Antonio J. , Nguyen, Minh-Doan T. , Martinez-Jorge, Jorys, Forte, Antonio Jorge , Bustos, S S , Kuruoglu, Doga , Boughey, Judy C.

Mayo Clinic

Plastic & Reconstructive Surgery | February 1, 2022 | Volume: 149 | Issue: 4 | Pages: 801-809

10.1097/prs.0000000000008895 | PMID 35103645 Get It

Background: Since its first description in 2012, the Goldilocks procedure has become an option for immediate breast reconstruction, particularly for obese patients who are poor candidates for traditional implant or autologous reconstruction. In this work, the authors performed a longitudinal study of patients who underwent mastectomy with Goldilocks reconstruction to assess the incidence of additional surgical procedures, and to assess surgical outcomes and patient satisfaction. Methods: A retrospective review of patients who underwent mastectomy with the Goldilocks procedure only at Mayo Clinic Rochester between January of 2012 and September of 2019 was performed. Demographics, complications, additional breast procedures performed to attain the final results, and patient-reported outcomes using the BREAST-Q were recorded. Univariate and multivariable analyses were performed to identify statistical associations and risk factors. Results: Sixty-three patients (108 breasts) were included. Mean age was 57.8 years. Mean body mass index was 37.6 kg/m2. Median follow-up time after the mastectomy with the Goldilocks procedure was 15 months. The major complication rate within the first 30 days was 9.3 percent. Forty-four breasts (40.7 percent) underwent additional surgery. Dyslipidemia was significantly associated with an increased risk of additional surgery (adjusted hazard ratio, 2.00; p = 0.045). Scores in the four BREAST-Q domains were not statistically different between patients who had additional procedures and those who did not. Conclusions: Based on the results, the authors recommend a thorough preoperative discussion with patients who are candidates for the Goldilocks procedure to explore all options for reconstruction and their expectations, because it is crucial to reduce the necessity for additional operations in this high-risk population. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.